Johnson & Johnson Innovation will host a virtual partnering event to actively engage with the German & DACH life sciences ecosystem and highlight how we interact with entrepreneurs, universities, startups and other innovators.
This will be relevant for innovators across all our therapeutic areas (Oncology, Immunology, Infectious Diseases & Vaccines, Cardio Vascular/Metabolic, Neuroscience), as well as for Medical Devices and Consumer Healthcare.
Given the travel and safety regulations in place to combat the coronavirus COVID-19 pandemic, the Johnson & Johnson Innovation team is looking to present its external collaboration model and meet life sciences start-ups across Europe through virtual events and 1:1 sessions.
The event will include an open briefing on the Johnson & Johnson Innovation model on November 17, followed by one-to-one partnering meetings with selected companies on November 17-18.
Apply to get the opportunity for a 1:1 meetings with the J&J Innovation cross-sectoral team by submitting a request before 20th of October. The full details of the event can be found here.
November 17, 10:30-12:00 CET
The Johnson & Johnson Innovation Model: Innovation Through Collaboration
A briefing on our goals and mission, highlighting how we interact with the entrepreneurial community through incubation (JLABS), investment (JJDC), early stage partnerships and deals (Innovation Centers), and late stage deals (Business Development).
Virtual Partnering Meetings
Companies/researchers/organizations that are based in Germany and interested in talking to the team in 1:1 virtual meeting need to apply by 20 October EOD CETby submitting their non-confidential information. Successful applicants will be invited to virtual 1:1 meetings with the Johnson & Johnson Innovation team on 17-18 November.